J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1203-1210. doi: 10.1016/j.japh.2023.05.007. Epub 2023 May 8.
Before the coronavirus disease 2019 (COVID-19) pandemic, 20% of the adult population in the United States experienced mental illness annually. Since the COVID-19 pandemic, 93% of countries have reported disruptions to mental health services. The demand for services is high whereas infrastructure and qualified professionals are appallingly low. Health care in the correctional setting is unique, where mental illness prevalence is double than that in the community. The intersection of policies and procedures and the beneficence plus nonmaleficence responsibility of health care professionals is exceptionally complex. Studies have shown the potential benefits of pharmacists following patients in chronic care psychiatry visits.
An inpatient psychiatric pharmacy clinic was launched to fill gaps to provide safe and up-to-date patient-centric services for more than 240 extremely psychiatrically ill inmate patients at the Federal Correctional Center Butner (FCC Butner), a Federal Bureau of Prisons medical center.
The inpatient psychiatric pharmacist practiced independently under a collaborative practice agreement and completed mental health clinical visits for a revolving portion of 240 inpatient mental health inmate patients at FCC Butner. The pharmacist provided ancillary services including completing movement disorder testing, monitoring narrow therapeutic index medication laboratory test results, and executing an antipsychotic psychoeducation meeting with other health care departments and inmate patients.
Notably, 74% of patients monitored in the specialty program experienced stable or improved symptoms of depression, schizophrenia, and bipolar disorder. Adverse effects, particularly psychiatric-related movement disorders, were also more closely managed. Finally, 43% of the total inmate patient population who previously declined psychiatric medication treatment consented to begin treatment after participation in a pilot antipsychotic psychoeducation meeting.
The inpatient psychiatric pharmacy program at FCC Butner is a dynamic program that has bolstered the facility's health care mission. The services detailed in this article can be applied to other correctional environments that have a medical outpatient or inpatient presence.
在 2019 年冠状病毒病（COVID-19）大流行之前，美国每年有 20%的成年人口经历精神疾病。自 COVID-19 大流行以来，93%的国家报告称精神卫生服务受到干扰。服务需求很高，而基础设施和合格的专业人员却低得令人震惊。惩教环境中的医疗保健是独特的，那里的精神疾病患病率是社区的两倍。政策和程序的交叉以及医疗保健专业人员的善行和不伤害责任异常复杂。研究表明，药剂师在慢性护理精神病学就诊中跟踪患者具有潜在益处。
启动了一个住院精神病学药房诊所，以填补空白，为联邦惩教中心布特纳（FCC Butner）的 240 多名极度精神病囚犯患者提供安全和最新的以患者为中心的服务，FCC Butner 是联邦监狱管理局的一个医疗中心。
根据合作实践协议，住院精神病学药剂师独立执业，为 FCC Butner 的 240 名住院精神科囚犯患者中的一部分轮流出诊。药剂师提供辅助服务，包括完成运动障碍测试、监测窄治疗指数药物实验室检测结果，并与其他医疗保健部门和囚犯患者一起执行抗精神病药物教育会议。
值得注意的是，在该专业计划中监测的 74%的患者经历了抑郁、精神分裂症和双相情感障碍的症状稳定或改善。此外，还更密切地管理了不良影响，特别是与精神相关的运动障碍。最后，在参加了一个试点抗精神病药物教育会议后，以前拒绝接受精神病药物治疗的 43%的总囚犯患者同意开始治疗。
FCC Butner 的住院精神病学药房计划是一个充满活力的计划，增强了该设施的医疗保健使命。本文详述的服务可以应用于其他具有医疗门诊或住院服务的惩教环境。
